Literature DB >> 25491506

G protein-coupled receptors: bridging the gap from the extracellular signals to the Hippo pathway.

Xin Zhou1, Zhen Wang2, Wei Huang3, Qun-Ying Lei4.   

Abstract

The Hippo pathway is crucial in organ size control, whereas its dysregulation contributes to organ degeneration or tumorigenesis. The kinase cascade of MST1/2 and LATS1/2 and the coupling transcription co-activators YAP/TAZ represent the core components of the Hippo pathway. Extensive studies have identified a number of upstream regulators of the Hippo pathway, including contact inhibition, mechanic stress, extracellular matrix stiffness, cytoskeletal rearrangement, and some molecules of cell polarity and cell junction. However, how the diffuse extracellular signals regulate the Hippo pathway puzzles the researchers for a long time. Unexpectedly, recent elegant studies demonstrated that stimulation of some G protein-coupled receptors (GPCRs), such as lysophosphatidic acid receptor, sphingosine-1-phosphate receptor, and the protease activated receptor PAR1, causes potent YAP/TAZ dephosphorylation and activation by promoting actin cytoskeleton assemble. In this review, we briefly describe the components of the Hippo pathway and focus on the recent progress with respect to the regulation of the Hippo pathway by GPCRs and G proteins in cancer cells. In addition, we also discuss the potential therapeutic roles targeting the Hippo pathway in human cancers.
© The Author 2014. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Entities:  

Keywords:  G proteins; GPCR; Hippo; TAZ; YAP; cancer

Mesh:

Substances:

Year:  2014        PMID: 25491506     DOI: 10.1093/abbs/gmu108

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  12 in total

Review 1.  The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines.

Authors:  Ilya S Senatorov; Nader H Moniri
Journal:  Biochem Pharmacol       Date:  2018-02-13       Impact factor: 5.858

Review 2.  Regulation of TAZ in cancer.

Authors:  Xin Zhou; Qun-Ying Lei
Journal:  Protein Cell       Date:  2016-07-14       Impact factor: 14.870

Review 3.  Repair Injured Heart by Regulating Cardiac Regenerative Signals.

Authors:  Wen-Feng Cai; Guan-Sheng Liu; Lei Wang; Christian Paul; Zhi-Li Wen; Yigang Wang
Journal:  Stem Cells Int       Date:  2016-10-09       Impact factor: 5.443

4.  The Hippo signaling pathway: a potential therapeutic target is reversed by a Chinese patent drug in rats with diabetic retinopathy.

Authors:  Gai-Mei Hao; Tian-Tian Lv; Yan Wu; Hong-Liang Wang; Wei Xing; Yong Wang; Chun Li; Zi-Jian Zhang; Zheng-Lin Wang; Wei Wang; Jing Han
Journal:  BMC Complement Altern Med       Date:  2017-04-04       Impact factor: 3.659

5.  Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas.

Authors:  Maribel Escoll; Diego Lastra; Marta Pajares; Natalia Robledinos-Antón; Ana I Rojo; Raquel Fernández-Ginés; Marta Mendiola; Virginia Martínez-Marín; Isabel Esteban; Pilar López-Larrubia; Ricardo Gargini; Antonio Cuadrado
Journal:  Redox Biol       Date:  2020-01-02       Impact factor: 11.799

Review 6.  A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas.

Authors:  Michael D Deel; Jenny J Li; Lisa E S Crose; Corinne M Linardic
Journal:  Front Oncol       Date:  2015-09-02       Impact factor: 6.244

Review 7.  New insights into posttranslational modifications of Hippo pathway in carcinogenesis and therapeutics.

Authors:  Mingjing He; Zhuan Zhou; Anil A Shah; Yang Hong; Qianming Chen; Yong Wan
Journal:  Cell Div       Date:  2016-03-31       Impact factor: 5.130

8.  Role of Yes-associated protein in cancer: An update.

Authors:  Ramazan Abylkassov; Yingqiu Xie
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

Review 9.  YAP/TAZ Activation as a Target for Treating Metastatic Cancer.

Authors:  Janine S A Warren; Yuxuan Xiao; John M Lamar
Journal:  Cancers (Basel)       Date:  2018-04-10       Impact factor: 6.639

Review 10.  Hippo Pathway in Regulating Drug Resistance of Glioblastoma.

Authors:  Giacomo Casati; Laura Giunti; Anna Lisa Iorio; Arianna Marturano; Luisa Galli; Iacopo Sardi
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.